Lymphoproliferative disease after renal transplantation in Australia and New Zealand

被引:100
作者
Faull, RJ [1 ]
Hollett, P
McDonald, SP
机构
[1] Royal Adelaide Hosp, Renal Unit, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Dept Med, Adelaide, SA 5000, Australia
[3] Nambour Gen Hosp, Renal Unit, Nambour, Qld, Australia
[4] Queen Elizabeth Hosp, ANZDATA Registry, Woodville, SA 5011, Australia
[5] Univ Adelaide, Dept Publ Hlth, Adelaide, SA 5005, Australia
关键词
renal transplantation; posttransplant lymphoproliferative disorder; lymphoma; cancer; Australia and New Zealand Dialysis and Transplant Registry Registry;
D O I
10.1097/01.TP.0000165098.49658.F3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Background. Lymphoproliferative disease is a common and serious complication of organ transplantation. It is wen documented that the risk of its development increases with the level of immunosuppression. Less is known about its incidence,'prevalence, timing, and prognosis. Methods. The authors conducted a retrospective review of all patients with lymphoproliferative disease after renal transplantation documented in the Australia and New Zealand Dialysis and Transplant Registry from 1970 to March 2003. Results. One hundred ninety-seven cases of lymphoproliferative disease occurred in 15,930 allografts in 13,516 recipients. There has been a steady increase in its incidence and prevalence each decade since 1970. Cases cluster into an early group (< 2 years after transplantation) and a late group (5-10 years after transplantation). Risk factors include exposure to a calcineurin inhibitor, but there was no increased risk in those treated with anti-T-lymphocyte antibodies. Patient survival was poor: 5 1 % at I I year. and 39% at 5 years. Conclusions. Lymphoproliferative disease is an increasingly common problem after renal transplantation, and the outcome is poor. Measures to reduce its incidence might include reduction of long-term immunosuppression exposure. Established disease has a high short-term mortality, and new treatment options, such as anti-B-lymphocyte monoclonal antibodies, should be aggressively pursued.
引用
收藏
页码:193 / 197
页数:5
相关论文
共 18 条
[1]
Risk of malignancy with long-term immunosuppression in renal transplant recipients [J].
Agraharkar, ML ;
Cinclair, RD ;
Kuo, YF ;
Daller, JA ;
Shahinian, VB .
KIDNEY INTERNATIONAL, 2004, 66 (01) :383-389
[2]
[Anonymous], 1999, APPL SURVIVAL ANAL T
[3]
Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient [J].
Aris, RM ;
Maia, DM ;
Neuringer, IP ;
Gott, K ;
Kiley, S ;
Gertis, K ;
Handy, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (06) :1712-1717
[4]
ARMITAGE JM, 1991, J HEART LUNG TRANSPL, V10, P877
[5]
CHAPMAN J, 2002, 25 REP AUSTR NZ DIAL, P84
[6]
POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RENAL-ALLOGRAFT RECIPIENTS - CLINICAL-EXPERIENCE AND RISK FACTOR-ANALYSIS IN A SINGLE-CENTER [J].
COCKFIELD, SM ;
PREIKSAITIS, JK ;
JEWELL, LD ;
PARFREY, NA .
TRANSPLANTATION, 1993, 56 (01) :88-96
[7]
LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN-TRANSPLANTATION - A REPORT OF 24 CASES OBSERVED IN A SINGLE-CENTER [J].
LEBLOND, V ;
SUTTON, L ;
DORENT, R ;
DAVI, F ;
BITKER, MO ;
GABARRE, J ;
CHARLOTTE, F ;
GHOUSSOUB, JJ ;
FOURCADE, C ;
FISCHER, A ;
GANDJBAKHCH, I ;
BINET, JL ;
RAPHAEL, M .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :961-968
[8]
ESRD in Australia and New Zealand at the end of the millennium: A report from the ANZDATA Registry [J].
McDonald, SP ;
Russ, GR ;
Kerr, PG ;
Collins, JF .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (06) :1122-1131
[9]
CLINICAL CHARACTERISTICS OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS [J].
MORRISON, VA ;
DUNN, DL ;
MANIVEL, JC ;
GAJLPECZALSKA, KJ ;
PETERSON, BA .
AMERICAN JOURNAL OF MEDICINE, 1994, 97 (01) :14-24
[10]
INCIDENCE OF NON-HODGKIN-LYMPHOMA IN KIDNEY AND HEART-TRANSPLANT RECIPIENTS [J].
OPELZ, G ;
HENDERSON, R .
LANCET, 1993, 342 (8886-7) :1514-1516